2Gorelick P B.Status of risk factors for dementia associated with stroke[J].stroke,1997,28(2):459-463.
3Fatahzadeh M,Glick M.Stroke:epidemiology,classification.risk factors,complications,diagnosis,prevention,and medical and dental management[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2006,102(2):180-191.
4Vernon M W,Sorkin E M.Piracetam.An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders[J].Drugs Aging,1991,1(1):17-35.
5Schenk F,Morris R G.Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions[J].Exp Brain Res,1985,58(1):11-28.
6Bradford M M.A rapid and sensitive method for the quatitation of microgram quantities of protein utilizing the principle of protein-dye binding[J].Anal Biochem,1976,72:248-254.
7Tsuchiya M,Sako K,Yura S,et al.Local cerebral glucose utilisation following acute and chronic bilateral carotid artery ligation in Wistar rats:relation to changes in local cerebral blood flow[J].Exp Brain Res,1993,95(1):1-7.
8Zs-Nagy I.Pharmacological interventions against aging through the cell plasma membrane:a review of the experimental results obtained in animals and humans[J].Ann N Y Acad Sci,2002,959:308-320.
9Ichikawa K,Tazawa S,Hamano S,et al.Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models[J].Pharmacology,1999,59(5):257-265.
10SoIntseva E I,Bukanova J V,Ostrovskaya R U,et al.The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels[J].Gen Pharmacol,1997,29(1):85-89.
